Riliprubart
- Generic Name
- Riliprubart
- Drug Type
- Biotech
- CAS Number
- 2756228-76-7
- Unique Ingredient Identifier
- I31869XDP8
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 160
- Registration Number
- NCT06290141
- Locations
- ๐บ๐ธ
Alabama Neurology Associates- Site Number : 8400019, Birmingham, Alabama, United States
๐บ๐ธPhoenix Neurological Associates - Phoenix- Site Number : 8400014, Phoenix, Arizona, United States
๐บ๐ธKeck School of Medicine of University of Southern California- Site Number : 8400002, Los Angeles, California, United States
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
- Conditions
- Chronic Inflammatory Demyelinating PolyradiculoneuropathyPolyneuropathy, Inflammatory Demyelinating, Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT06290128
- Locations
- ๐บ๐ธ
Alabama Neurology Associates- Site Number : 8400019, Birmingham, Alabama, United States
๐บ๐ธUSC Norris Comprehensive Cancer Center- Site Number : 8400002, Los Angeles, California, United States
๐บ๐ธUniversity of California Irvine - Manchester Pavilion- Site Number : 8400007, Orange, California, United States
Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Bioverativ, a Sanofi company
- Target Recruit Count
- 9
- Registration Number
- NCT04802057
- Locations
- ๐ฌ๐ง
Investigational Site Number : 8260001, London, London, City Of, United Kingdom
๐ณ๐ดInvestigational Site Number : 5780001, Bergen, Norway
๐ฎ๐นInvestigational Site Number : 3800001, Milano, Italy
A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin Disease
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Bioverativ, a Sanofi company
- Target Recruit Count
- 12
- Registration Number
- NCT04269551
- Locations
- ๐ณ๐ฑ
Investigational Site Number :5280001, Amsterdam, Netherlands
๐ณ๐ดInvestigational Site Number :5780001, Bergen, Norway
๐บ๐ธInvestigational Site Number :8400008, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.